Apex Biotechnology Corp Cash Flow Conversion Efficiency
Apex Biotechnology Corp cash flow conversion efficiency. Based on the latest financial reports, Apex Biotechnology Corp (1733) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$5.19 Million ≈ $163.42K USD) by net assets (NT$1.81 Billion ≈ $57.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Apex Biotechnology Corp (2002–2024)
Cash flow conversion efficiency of Apex Biotechnology Corp from 2002 to 2024. This chart illustrates how Apex Biotechnology Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Apex Biotechnology Corp share price for real-time trading data and today's change.
Apex Biotechnology Corp Cash Flow Conversion Ratio Explained
Apex Biotechnology Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Apex Biotechnology Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apex Biotechnology Corp ranked by their cash flow conversion efficiency. Also see market value of Apex Biotechnology Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Likhitha Infrastructure Limited
NSE:LIKHITHA
|
-0.026x |
|
Tae Kyung Ind
KO:015890
|
0.011x |
|
Hongli Group Inc. Ordinary Shares
NASDAQ:HLP
|
0.020x |
|
MLG OZ Ltd
AU:MLG
|
0.297x |
|
OncoCyte Corp
NASDAQ:OCX
|
-0.573x |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
0.063x |
|
Kumho Petro Chemical Co Ltd
KO:011785
|
0.001x |
|
Barington/Hilco Acquisition
NASDAQ:BHAC
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Apex Biotechnology Corp (2002–2024)
The table below shows the annual cash flow conversion efficiency of Apex Biotechnology Corp from 2002 to 2024. Review 1733 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.82 Billion ≈ $57.47 Million |
NT$328.67 Million ≈ $10.35 Million |
0.180x | +40.52% |
| 2023-12-31 | NT$1.80 Billion ≈ $56.61 Million |
NT$230.39 Million ≈ $7.26 Million |
0.128x | +775.71% |
| 2022-12-31 | NT$1.82 Billion ≈ $57.27 Million |
NT$26.62 Million ≈ $838.55K |
0.015x | -85.73% |
| 2021-12-31 | NT$1.75 Billion ≈ $55.25 Million |
NT$179.87 Million ≈ $5.67 Million |
0.103x | -39.83% |
| 2020-12-31 | NT$1.65 Billion ≈ $51.86 Million |
NT$280.60 Million ≈ $8.84 Million |
0.170x | -38.20% |
| 2019-12-31 | NT$1.68 Billion ≈ $52.83 Million |
NT$462.52 Million ≈ $14.57 Million |
0.276x | +571.12% |
| 2018-12-31 | NT$1.64 Billion ≈ $51.79 Million |
NT$67.57 Million ≈ $2.13 Million |
0.041x | -3.39% |
| 2017-12-31 | NT$1.66 Billion ≈ $52.45 Million |
NT$70.83 Million ≈ $2.23 Million |
0.043x | -75.27% |
| 2016-12-31 | NT$1.73 Billion ≈ $54.58 Million |
NT$298.06 Million ≈ $9.39 Million |
0.172x | -29.67% |
| 2015-12-31 | NT$1.93 Billion ≈ $60.80 Million |
NT$472.15 Million ≈ $14.88 Million |
0.245x | +70.64% |
| 2014-12-31 | NT$1.87 Billion ≈ $58.80 Million |
NT$267.60 Million ≈ $8.43 Million |
0.143x | -43.20% |
| 2013-12-31 | NT$1.92 Billion ≈ $60.51 Million |
NT$484.77 Million ≈ $15.27 Million |
0.252x | -0.31% |
| 2012-12-31 | NT$2.01 Billion ≈ $63.41 Million |
NT$509.67 Million ≈ $16.06 Million |
0.253x | +62.08% |
| 2011-12-31 | NT$1.75 Billion ≈ $55.14 Million |
NT$273.45 Million ≈ $8.62 Million |
0.156x | -45.31% |
| 2010-12-31 | NT$1.63 Billion ≈ $51.35 Million |
NT$465.59 Million ≈ $14.67 Million |
0.286x | +7.41% |
| 2009-12-31 | NT$1.47 Billion ≈ $46.35 Million |
NT$391.29 Million ≈ $12.33 Million |
0.266x | +12.09% |
| 2008-12-31 | NT$1.26 Billion ≈ $39.83 Million |
NT$299.96 Million ≈ $9.45 Million |
0.237x | -12.21% |
| 2007-12-31 | NT$1.35 Billion ≈ $42.50 Million |
NT$364.62 Million ≈ $11.49 Million |
0.270x | -18.07% |
| 2006-12-31 | NT$1.10 Billion ≈ $34.74 Million |
NT$363.71 Million ≈ $11.46 Million |
0.330x | +39.47% |
| 2005-12-31 | NT$896.93 Million ≈ $28.26 Million |
NT$212.14 Million ≈ $6.68 Million |
0.237x | -6.29% |
| 2004-12-31 | NT$865.91 Million ≈ $27.28 Million |
NT$218.54 Million ≈ $6.89 Million |
0.252x | -29.66% |
| 2003-12-31 | NT$842.42 Million ≈ $26.54 Million |
NT$302.25 Million ≈ $9.52 Million |
0.359x | +221.73% |
| 2002-12-31 | NT$712.76 Million ≈ $22.46 Million |
NT$79.49 Million ≈ $2.50 Million |
0.112x | -- |
About Apex Biotechnology Corp
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health s… Read more